Novo Nordisk’s weight-loss medication Wegovy (semaglutide) was approved in Japan in March. While it skipped the May round of reimbursement listing, physicians eagerly await the arrival of what would be the first new obesity drug in three decades. Other companies…
BUSINESS
Mylan Japan Offers Severance Package for 110 Sales Reps
A Japan arm of major generic maker Mylan, Mylan Seiyaku, is offering a severance package for some 110 sales reps who will return from Pfizer Japan, the company’s partner in the generic business in the country, at the end of…
To read the full story
Related Article
- Mylan Japan Labor Union, Management Reach Settlement; All 14 Members to Leave on May 31
May 30, 2016
- Mylan Japan Management, Labor Union Remain at Odds over Sales Rep Layoff
April 21, 2016
- Mylan Japan Labor Union Raps Management over “Effective Dismissal”, No Progress Made in 1st Round of Negotiations
April 6, 2016
- Japan Units of Abbott, Mylan to Run Separate Operations for Now
March 4, 2015
- All Eyes Glued to Japan Realignment after Mylan’s Buyout of Abbott’s Established Product Biz
September 8, 2014
- Mylan Generics Will Be Distributed under Pfizer Brand Next Year: Pfizer’s Matsumori
July 17, 2013
- Pfizer-Mylan Pair’s Japan Generic Share at 2.8%, Aspire for Bigger Slice of Market
April 22, 2013
- Pfizer Confident about Joining Top 3 in Japan Generic Sales by around 2015: Unit Chief Matsumori
February 7, 2013
- Pfizer, Mylan Ink Strategic Collaboration in Japan Generics Biz; Aim for No. 3 in Market
August 24, 2012
BUSINESS
- AbbVie Aims to Double Japan Sales to 200 Billion Yen by 2030: Local Chief
May 31, 2023
- Jeremy Grossas to Head Up Merck Biopharma Japan
May 30, 2023
- Nobelpharma Gets EU Nod for Hyftor
May 30, 2023
- Pfizer Japan Files RSV Vaccine for 60 Years of Age and Older
May 29, 2023
- Chugai’s FoundationOne Liquid Wins Approval as Tabrecta CDx
May 29, 2023
President Joe Biden enacted the Inflation Reduction Act (IRA) on August 16, 2022, significantly affecting Medicare prescription drug coverage and introducing targeted changes to Medicaid, the Children’s Health Insurance Program, and private health insurance. In January 2023, the Centers for…
Japan’s health ministry on April 27 presented an outline of a report to be compiled next month by its key…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…